Researchers at The University of Texas MD Anderson Cancer Center have identified that resistance to tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) is driven by severe mutations in the TET2 gene and reduced expression of the TXNRD1 enzyme. Published in the journal Leukemia, the study provides a potential framework for using these molecular markers to predict patient response and personalize BPDCN treatment.
Why does tagraxofusp resistance occur in BPDCN?
Tagraxofusp, the first FDA-approved therapy for BPDCN, acts as a targeted “toxin-delivery” system. It identifies and binds to CD123, a surface marker overexpressed in BPDCN cells. Once the drug enters the cell, it releases a toxin that halts protein production, killing the cancer cell. However, MD Anderson researchers found that some cancer cells survive by “dialing down” the TXNRD1 enzyme, which acts as a release switch for the toxin.
According to the study, led by Hannah Beird, Ph.D., and Naveen Pemmaraju, M.D., when TXNRD1 levels are low, the drug’s toxin remains trapped inside the cell, rendering the treatment ineffective. The researchers identified a specific group of resistant cells, labeled “cluster 22,” which consistently showed this enzyme deficiency.
BPDCN is an aggressive, rare form of leukemia that typically originates from a specialized type of immune cell found in bone marrow. Because of its rarity and the limited number of treatment options, identifying biomarkers for drug resistance is a major priority for clinical outcomes.
How can TET2 mutations predict treatment outcomes?
The molecular analysis revealed that the status of the TET2 gene serves as a critical prognostic biomarker. Patients with normal or mild TET2 mutations demonstrated a higher likelihood of responding to tagraxofusp. In contrast, those with severe TET2 mutations were more likely to develop resistance, as these mutations appear to promote the low-TXNRD1 state that allows cancer cells to escape destruction.
By utilizing single-cell sequencing on nearly 100,000 cells, the team established a clear link between genetic profile and clinical success. Dr. Beird noted that understanding these mechanisms allows clinicians to design smarter, more personalized treatment strategies for patients who might otherwise struggle to respond to standard therapy.
What are the future implications for leukemia therapy?
The researchers suggest that monitoring TXNRD1 levels could alert clinicians to patients who are beginning to develop resistance during the course of treatment. Furthermore, the study points to the potential for combination therapies. Preclinical models showed that pairing tagraxofusp with a hypomethylating agent, such as azacitidine, successfully restored key pathways and improved outcomes.
Dr. Pemmaraju stated that these findings may serve as a blueprint for other rare blood cancers. By investigating the resistance phenomena in BPDCN, researchers hope to apply similar diagnostic and therapeutic techniques to other, more common tumor types that exhibit comparable resistance patterns.
Frequently Asked Questions
What is BPDCN?
BPDCN is an aggressive, rare type of acute leukemia that usually develops from a specific immune cell in the bone marrow. It is characterized by limited treatment options and a generally poor prognosis.
How does tagraxofusp work?
Tagraxofusp targets CD123 on the surface of BPDCN cells. After binding, the drug enters the cell and releases a toxin that shuts down protein production, causing the cell to die.
Can doctors test for tagraxofusp resistance?
Yes, the study suggests that checking for TET2 mutations can help identify which patients are most likely to benefit. Additionally, monitoring TXNRD1 enzyme levels may help clinicians detect when a patient is developing resistance.
Are there ways to overcome this resistance?
Evidence from the study suggests that combining tagraxofusp with hypomethylating agents, like azacitidine, can help restore pathways and improve treatment efficacy in resistant models.
For more updates on breakthroughs in leukemia research and targeted cancer therapies, subscribe to our newsletter or explore our archive of oncology clinical trial reports.
